Fu-kun Zhao

Dr. Fu-kun Zhao


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2023 in Medicine
Verified
Journal Article
Open access
FTFei Tang
Fei Tang
CJChanggui Bd Jiang
Changgui Bd Jiang
JCJun Bd Chen
Jun Bd Chen
LWLiangyong Bd Wang
Liangyong Bd Wang
FZFu-kun Zhao
Fu-kun Zhao
Myofascial Pain Syndrome (MPS) is a prevalent disease, and the related literature research has been increasing in recent years. However, there is a lack of scientific and comprehensive bibliometric analyses in the MPS research field. This study aimed to summarize and visualize the literature distribution laws, research hotspots and development trends in MPS based on bibliometric methods. Relevant literature on MPS research from 1956 to 2022 was retrieved from the Web of Science Core Collection database. Quantitative and visual analyses of the collected literature were performed using Microsoft Office 2021, Bibliometrics, VOSviewer, and CiteSpace. A total of 1099 papers were included, and the number of papers in this research field is generally upward. The USA has the most publications (270), and Univ Sao Paulo is the institution with the most publications (31). Hong CZ and Calvo-Lobo C have the same number of publications and are the authors with the most publications (20), and Simons DG is the author with the most co-citations (1078). Journal of Musculoskeletal Pain is the journal with the most publications (61), and Pain is the journal with the most co-cited papers (2598) and the highest impact factor (7.926). Lidocaine injection versus dry needling to myofascial trigger point. The importance of the local twitch response is the reference with the highest number of co-citations (136). The top 5 keywords in this period are myofascial pain syndrome (571), trigger points (218), pain (97), myofascial pain (92), and myofascial trigger point (80). The keywords of recent bursts are dry needling (2016–2022), efficacy (2020–2022), validity (2020–2022), temporomandibular joint disorder (2020–2022), and orofacial pain (2020–2022). This study summarizes and visualizes the evolution, research hotspots, and future trends of the global MPS domain from 1956 to 2022. It is helpful for scholars to understand the general situation of MPS research quickly and provide a reference for clinical decision-making and future research directions.

9 August 2024 in Medicine
Verified
Journal Article
Open access
FTFei Tang
Fei Tang
FZFu-kun Zhao
Fu-kun Zhao
YJYong Bd Jiang
Yong Bd Jiang
TZTao Bd Zhang
Tao Bd Zhang
BWBangfeng Bd Wang
Bangfeng Bd Wang
Diabetic peripheral neuropathy (DPN) is a prevalent disease, and the relevant literature has been increasingly investigated over the past years. Consequently, it is imperative to conduct a scientific and comprehensive DPN research field bibliometric analysis. This study aims to summarize and visualize the literature distribution laws, the research hotspots, and the development trends in DPN using bibliometric methods. We searched all relevant documents published from 2011 to 2023 in the Web of Science Core Collection. Bibliometric analysis and network visualization were performed using VOSviewer, R-bibliometrix, and CiteSpace tools, focusing on countries, institutions, authors, journals, highly cited papers, references, and keywords. This study included a total of 2708 documents. The annual number of publications in the field has notably increased. China, the USA, and the UK take on critical significance in DPN research. The University of Manchester in the UK has the highest number of publications (109). Malik has the most publications (86). Tesfaye literature has been most frequently cited by scholars of DPN research. The Journal of Diabetes and its Complications and Frontiers in Endocrinology have the most publications (45 each). Diabetes Care stands out with the highest impact factor (16.200), number of citations (2516), and H-index (27) among the number of publications top 10 journals. The paper “Colloca, L. et al Neuropathic pain. Nature Reviews Disease Primers. 2017, 3 (1):1–19” has the highest number of citations (1224 times). The most critical co-cited reference is “Tesfaye S, 2010, DIABETES CARE, V33, P2285” (cited 408 times). Keywords like “type 2 diabetes,” “diagnosis,” “association,” “retinopathy,” “risk factors,” “progression,” “corneal confocal microscopy,” “nephropathy,” “balance,” “microvascular complications,” “inflammation,” “disease,” and “insulin resistance” represent the recent research hotspots. The development, research hotspots, and future trends of the global DPN domain from 2011 to 2023 were summarized and visualized in this study. This study can present more insights into the general situation of DPN research and provide a useful reference for clinical decision-making and directions of subsequent research.

30 June 2026 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
FZFu-kun Zhao
Fu-kun Zhao
FZFu-kun Zhao
Fu-kun Zhao
Background: In 2020, an estimated 14.9 million herpes zoster (HZ) cases occurred worldwide among adults aged ≥ 50 years; this number is projected to rise to 19.1 million by 2030. Postherpetic neuralgia (PHN), the most common complication of HZ, develops in 5% to > 30% of patients with HZ. Poorly managed PHN may cause persistent pain, functional impairment, psychological distress, and, in severe cases, suicide. This review summarizes the current evidence on PHN and proposes a tiered management framework. Methods: PubMed and Web of Science were searched for PHN‐related articles published from January 2011 to December 2025, with reference‐list screening. Studies were selected by clinical relevance and design. Management strategies were tiered by guideline support, regulatory approval, and PHN‐specific efficacy and safety evidence. Results: Pathogenesis involves viral reactivation, peripheral and central sensitization, and genetic modulation. Major risk factors include older age, severe acute pain, extensive rash, craniofacial/thoracic involvement, immunocompromise, comorbidities, and treatment delay. Management of PHN is tiered: Tier 1 treatments include gabapentinoids, the 5% lidocaine patch, tricyclic antidepressants, duloxetine, and the 8% capsaicin patch; Tier 2 treatments include botulinum toxin type A injections, pulsed radiofrequency, and temporary spinal cord stimulation (tSCS); and Tier 3 options include opioids and neuromodulation. Conclusions: PHN remains the most common and therapeutically challenging complication of HZ. Although a stratified framework for PHN management has been proposed, it still requires validation in clinical practice and further refinement to support more effective individualized treatment.

15 July 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
FZFu-kun Zhao
Fu-kun Zhao
MLMin Luo
Min Luo
YWYuanmin Wang
Yuanmin Wang
MSMu Su
Mu Su
FTFei Tang
Fei Tang
Objective: To detect muscular system adverse reaction signals of sacubitril/valsartan treatment combined with statins (atorvastatin, rosuvastatin, simvastatin) to provide a reference for clinical administration.Methods: Multiplicative and additive models were used to mine the FDA’s spontaneous reports database to detect signals of drug-drug interactions between sacubitril/valsartan and statins. SAS 9.4 software was used to conduct statistical tests for suspicious signals to determine whether the signals were statistically significant.Results: A total of 8,883,870 adverse reaction reports were analyzed. The combinations “sacubitril/valsartan - simvastatin - musculoskeletal muscle pain” had statistically significant correlation signals in both models (P < 0.05). The combination “sacubitril/valsartan - atorvastatin - myopathy” and “sacubitril/valsartan–simvastatin - myopathy” had statistically significant correlation signal in the multiplicative model (P < 0.05).Conclusion: Compared with a single drug, coadministration of sacubitril/valsartan with atorvastatin may increase safety risks to myopathy, with simvastatin may increase safety risks to the musculoskeletal pain and myopathy, which should be closely monitored in clinical practice.


5 June 2026 in Medicine
Verified
Journal Article
Open access
FTFei Tang
Fei Tang
FZFu-kun Zhao
Fu-kun Zhao
YJYong Bd Jiang
Yong Bd Jiang
BWBangfeng Bd Wang
Bangfeng Bd Wang
YLYimei Bd Li
Yimei Bd Li
Postherpetic neuralgia (PHN) is a disabling complication of herpes zoster (HZ). Early identification of high-risk patients may enable targeted prevention and follow-up. We developed and compared machine-learning models for PHN prediction using the Medical Information Mart for Intensive Care IV database and identified key predictors. This retrospective cohort study used Medical Information Mart for Intensive Care IV v2.2 (2008–2019). Adult inpatients with HZ were identified via International Classification of Diseases-9/10 codes (053.x or B02.x). The outcome was PHN (binary). Candidate predictors included demographics, pain phenotypes, comorbidities, laboratory markers, and inpatient medications; an antiviral initiation delay ≥ 3 days (AVdelay3d) was derived. Data were split into stratified training/validation sets (70/30). Five-fold cross-validation with Bayesian optimization was applied for categorical boosting, light gradient-boosting machine, extreme gradient boosting (XGBoost), and adaptive boosting; least absolute shrinkage and selection operator logistic regression was tuned via cross-validation. Discrimination was assessed by area under the receiver operating characteristic curve; the optimal probability threshold was determined by maximizing the Youden index. Feature selection used Boruta and least absolute shrinkage and selection operator, supplemented by feature importance from the best-performing model. All models were validated internally using the same dataset, and no external validation was performed. Of 383 inpatients with HZ, 81 (21.1%) developed PHN. XGBoost achieved the best discrimination (area under the receiver operating characteristic curve = 0.737; 95% confidence interval: 0.652–0.822). Baseline comparisons showed that PHN risk was associated with a higher maximum pain score, AVdelay3d, diabetes, amitriptyline use, a lower hematocrit level, and severe immunosuppression (all P < .05). In the Boruta analysis, the confirmed important features (in descending order) were D-dimer, hematocrit, creatinine, AVdelay3d, age, and platelet count. In the PHN prediction model, tree-based methods (e.g., XGBoost) can effectively estimate PHN risk and outperform linear models. These findings suggest that the pathogenesis of PHN may involve complex, nonlinear interactions. Baseline comparisons and feature-importance analyses further identified a set of core predictors for PHN, providing a reference for early identification of high-risk patients and for implementing risk-stratified management. However, the results should be interpreted cautiously because only internal validation was performed, and external validation was lacking.